• Something wrong with this record ?

Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study

SH. Hohnloser, J. Camm, R. Cappato, HC. Diener, H. Heidbuchel, HJ. Lanz, L. Mont, CA. Morillo, R. Smolnik, OQP. Yin, J. Kautzner,

. 2018 ; 41 (4) : 440-449. [pub] 20180417

Language English Country United States

Document type Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc18033151

Patients with atrial fibrillation (AF) are at an approximately 0.5% to 3% increased risk of thromboembolism during and immediately after catheter ablation. Treatment guidelines recommend periprocedural oral anticoagulation plus unfractionated heparin during ablation. Rivaroxaban and dabigatran are the only non-vitamin K oral anticoagulants for which there are randomized controlled trials assessing uninterrupted anticoagulation in patients undergoing catheter ablation of AF. Edoxaban, a direct factor Xa inhibitor, is noninferior vs warfarin for the prevention of stroke or systemic embolism with less major bleeding in patients with nonvalvular AF. The ELIMINATE-AF (Evaluation of Edoxaban Compared With VKA in Subjects Undergoing Catheter Ablation of Nonvalvular Atrial Fibrillation) trial is a multinational, multicenter, prospective, randomized, open-label, parallel-group, blinded-endpoint evaluation (PROBE) study to assess the safety and efficacy of once-daily edoxaban 60 mg (30 mg in patients indicated for a dose reduction) vs vitamin K antagonists (VKA) in patients with nonvalvular AF undergoing catheter ablation (http://www.ClinicalTrials.gov: NCT02942576). A total of 560 patients are planned for randomization to edoxaban or VKA (2:1 ratio) to obtain 450 patients fully compliant with the protocol. Patients will complete 21 to 28 days of anticoagulation prior to the ablation and a 90-day post-ablation period. The primary efficacy endpoint is the composite of all-cause death, stroke, and major bleeding. The primary safety endpoint is major bleeding. A magnetic resonance imaging substudy will assess the incidence of silent cerebral lesions post-ablation. ELIMINATE-AF will define the efficacy and safety of edoxaban for uninterrupted oral anticoagulation during catheter ablation of AF.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033151
003      
CZ-PrNML
005      
20210304151732.0
007      
ta
008      
181008s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/clc.22918 $2 doi
035    __
$a (PubMed)29663464
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hohnloser, Stefan H $u Division of Clinical Electrophysiology, Department of Cardiology, J.W. Goethe University, Frankfurt, Germany.
245    10
$a Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study / $c SH. Hohnloser, J. Camm, R. Cappato, HC. Diener, H. Heidbuchel, HJ. Lanz, L. Mont, CA. Morillo, R. Smolnik, OQP. Yin, J. Kautzner,
520    9_
$a Patients with atrial fibrillation (AF) are at an approximately 0.5% to 3% increased risk of thromboembolism during and immediately after catheter ablation. Treatment guidelines recommend periprocedural oral anticoagulation plus unfractionated heparin during ablation. Rivaroxaban and dabigatran are the only non-vitamin K oral anticoagulants for which there are randomized controlled trials assessing uninterrupted anticoagulation in patients undergoing catheter ablation of AF. Edoxaban, a direct factor Xa inhibitor, is noninferior vs warfarin for the prevention of stroke or systemic embolism with less major bleeding in patients with nonvalvular AF. The ELIMINATE-AF (Evaluation of Edoxaban Compared With VKA in Subjects Undergoing Catheter Ablation of Nonvalvular Atrial Fibrillation) trial is a multinational, multicenter, prospective, randomized, open-label, parallel-group, blinded-endpoint evaluation (PROBE) study to assess the safety and efficacy of once-daily edoxaban 60 mg (30 mg in patients indicated for a dose reduction) vs vitamin K antagonists (VKA) in patients with nonvalvular AF undergoing catheter ablation (http://www.ClinicalTrials.gov: NCT02942576). A total of 560 patients are planned for randomization to edoxaban or VKA (2:1 ratio) to obtain 450 patients fully compliant with the protocol. Patients will complete 21 to 28 days of anticoagulation prior to the ablation and a 90-day post-ablation period. The primary efficacy endpoint is the composite of all-cause death, stroke, and major bleeding. The primary safety endpoint is major bleeding. A magnetic resonance imaging substudy will assess the incidence of silent cerebral lesions post-ablation. ELIMINATE-AF will define the efficacy and safety of edoxaban for uninterrupted oral anticoagulation during catheter ablation of AF.
650    _2
$a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $7 D000925
650    _2
$a fibrilace síní $x komplikace $x mortalita $x patofyziologie $x chirurgie $7 D001281
650    _2
$a ischemie mozku $x diagnostické zobrazování $x etiologie $x prevence a kontrola $7 D002545
650    12
$a katetrizační ablace $x škodlivé účinky $x mortalita $7 D017115
650    _2
$a klinické protokoly $7 D002985
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a inhibitory faktoru Xa $x aplikace a dávkování $x škodlivé účinky $7 D065427
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x chemicky indukované $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    _2
$a pyridiny $x aplikace a dávkování $x škodlivé účinky $7 D011725
650    _2
$a výzkumný projekt $7 D012107
650    _2
$a rizikové faktory $7 D012307
650    _2
$a cévní mozková příhoda $x diagnostické zobrazování $x etiologie $x prevence a kontrola $7 D020521
650    _2
$a thiazoly $x aplikace a dávkování $x škodlivé účinky $7 D013844
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vitamin K $x antagonisté a inhibitory $7 D014812
650    _2
$a warfarin $x aplikace a dávkování $x škodlivé účinky $7 D014859
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Camm, John $u Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's University of London, London, UK.
700    1_
$a Cappato, Riccardo $u Arrhythmia and Electrophysiology Research Center, Humanitas Clinical and Research Center, Rozzano, Italy.
700    1_
$a Diener, Hans-Christoph $u Department of Neurology, University Hospital Essen and Medical Faculty of the University Duisburg-Essen, Essen, Germany.
700    1_
$a Heidbüchel, Hein $u Department of Cardiology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium. $7 xx0257830
700    1_
$a Lanz, Hans-Joachim $u Department of Global Medical Affairs, Daiichi-Sankyo Europe GmbH, Munich, Germany.
700    1_
$a Mont, Lluís $u Department of Cardiology, Hospital Clinic, University of Barcelona, Barcelona, Spain.
700    1_
$a Morillo, Carlos A $u Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.
700    1_
$a Smolnik, Rüdiger $u Department of Global Medical Affairs, Daiichi-Sankyo Europe GmbH, Munich, Germany.
700    1_
$a Yin, Ophelia Q P $u Pharma Development, Modeling, and Simulation, Daiichi-Sankyo, Basking Ridge, New Jersey.
700    1_
$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
773    0_
$w MED00001122 $t Clinical cardiology $x 1932-8737 $g Roč. 41, č. 4 (2018), s. 440-449
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29663464 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20210304151645 $b ABA008
999    __
$a ok $b bmc $g 1339382 $s 1030145
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 41 $c 4 $d 440-449 $e 20180417 $i 1932-8737 $m Clinical cardiology $n Clin Cardiol $x MED00001122
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options